SCLC Consortium: Therapeutic Development and Mechanisms of Resistance (2.17.18)

January 2, 2018
By: Julie Poucher Harbin, Writer, DCI

Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01)

Funding Agency: National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.

This FOA focuses on two of the five research priorities identified in the National Cancer Institute’s 2014 Scientific Framework for Small Cell Lung Cancer (SCLC). Additional priorities of the Framework are stated in this FOA, as studies are expected to use or develop state-of-the-art research tools and –omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance.

The research supported by this FOA will be performed by individual research teams who are expected to collaborate with one another and with a central SCLC Coordinating Center. A third component of the SCLC Consortium focuses on prevention and early detection of SCLC. 

Companion FOAs of the SCLC Consortium include:

  • PAR-16-051, "SCLC Consortium: Innovative Approaches to the Diagnosis and Prevention of SCLC (U01)" and;
  • PAR-16-050, "Coordinating Center for Small Cell Lung Cancer (SCLC) Consortium (U24)."

Areas Of Interest: 

This FOA addresses the last two recommendations, which are: 

1. to focus on therapeutic development efforts, particularly on specific molecular vulnerabilities of SCLC; and

2. to examine mechanisms underlying both the high initial rate of response to primary SCLC therapy and the rapid emergence of drug and radiation resistance following completion of treatment. 

Additional priorities of the Framework are encompassed in this FOA, as studies are expected to use or develop state-of-the-art research tools and –omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance.

Funding Amount: $1,350,000

Budgets are limited to $450,000 Direct Costs (excluding consortium F&A costs) per year. Budgets should reflect the actual needs of the proposed project and non-modular budgets require extensive justification.

The maximum project period is five years.  

Application Deadlines: 

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): March 17, 2018; November 17, 2018, by 5:00 PM local time of applicant organization.

Eligibility: Faculty

For more Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-049.html